Recent Updates
Recently added Catalysts
MLTX Negative Sentiment

MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MLTX

Key Takeaway: MoonLake Immunotherapeutics is being sued for securities law violations as a class action lawsuit pertains to misleading claims about its drug candidate SLK. The allegations state that the company failed to properly disclose the lack of clinical superiority of SLK over traditional monoclonal treatments. Shareholders who purchased stock during the specified class period are encouraged to participate in the lawsuit, with a registration deadline looming.
Price reaction · baseline $12.52 (2025-12-02 close) · hit after-hours · 3 other MLTX headline(s) in the window, move may be shared
day 0 close
+6.6%
day 1
+19.8%
day 3 · peak
+20.4%

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake Immunotherapeutics is facing a securities class action lawsuit due to allegations of misleading statements regarding its drug candidate, SLK.
  • The lawsuit claims that SLK's distinct Nanobody structure does not provide a superior clinical benefit compared to existing treatments.
  • Investors are encouraged to register for the class action, indicating potential for significant legal and financial repercussions for the company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
4.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Sonelokimab
Phase 3 · Hidradenitis Suppurativa

Full Press Release Details

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 10, 2024 to September 29, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
DEADLINE: December 15, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=179485&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MLTX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 15, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor

Frequently Asked Questions

What is the class period for MoonLake Immunotherapeutics?

The class period for MoonLake Immunotherapeutics is from March 10, 2024, to September 29, 2025.

What are the allegations against MoonLake Immunotherapeutics?

The allegations include misleading statements about SLK's clinical benefits compared to BIMZELX.

What is the deadline to register for the class action?

The deadline to register for the class action is December 15, 2025.

Do I have to be a lead plaintiff to participate?

No, you do not need to be a lead plaintiff to participate in the recovery.

What will happen after I register as a shareholder?

After registering, you will receive status updates via a portfolio monitoring software.

Last updated: Dec 3, 2025